Key result
Impaired glucose tolerance with albuminuria is linked to ~2.2-fold higher risk of major cardiovascular events.
Why the study?
The study was designed to evaluate the prognostic significance of impaired glucose tolerance with reference to albuminuria in patients with chronic heart failure.
Does impaired glucose tolerance combined with albuminuria worsen long-term cardiovascular outcomes in patients with chronic heart failure?
Cohort (n=535)
Yes
Does impaired glucose tolerance combined with albuminuria worsen long-term cardiovascular outcomes in patients with chronic heart failure?
The combination of impaired glucose tolerance and albuminuria identifies a subgroup of chronic heart failure patients at significantly higher risk for adverse cardiovascular events.
Answers are grounded in this paper and cite their sources.
May support risk stratification in chronic HF; leaves open whether targeted interventions improve outcomes.
AIMS: The study aims to evaluate the prognostic significance of impaired glucose tolerance (IGT) with reference to albuminuria in patients with chronic heart failure (CHF). METHODS AND RESULTS: We examined 535 CHF patients (mean 66 years, women 25%) in the control arm of our SUPPORT trial, in which we examined additive impact of olmesartan in hypertensive patients with symptomatic CHF treated with β-blockers and/or angiotensin-converting enzyme inhibitors. We examined the association between glycaemic abnormality (assessed by 75 g of oral glucose tolerance test) and albuminuria for a composite outcome of all-cause death, myocardial infarction, stroke, and HF hospitalization. IGT patients (N = 113, mean 67.2 years) were older and more frequently treated with β-blockers compared with those with normal glucose regulation (N = 142, mean 64.0 years) and those with diabetes mellitus (N = 280, mean 65.7 years). Multivariable Cox proportional hazard models revealed that, as compared with normal glucose regulation (NGR), IGT was associated with increased risk of the outcome when complicated by albuminuria [hazard ratio (HR) 2.25; 95% confidence interval (CI) 1.14-4.42; P = 0.019] but not when uncomplicated by albuminuria (HR 0.76; 95% CI 0.35-1.60, P = 0.47) (P for interaction = 0.041). This was also the case for diabetes mellitus and albuminuria (HR 2.06; 95% CI 1.17-3.61; P = 0.012). Among IGT patients without albuminuria, 21 (29%) developed albuminuria at 1-year visit, which was again associated with poor prognosis (HR 7.36; 95% CI 1.39-38.98, P = 0.019). CONCLUSIONS: These results indicate that IGT is associated with poor prognosis when complicated by albuminuria in CHF patients, demonstrating the importance of combined early stages of glucose intolerance and renal dysfunction in the management of CHF.
No takes yet. Share an insight, caveat, or question.
Nochioka et al. (2019) conducted a cohort in Chronic heart failure (CHF) (n=535). Impaired glucose tolerance (IGT) complicated by albuminuria vs. Normal glucose regulation (NGR) without albuminuria was evaluated on Composite of all-cause death, non-fatal myocardial infarction, non-fatal stroke, and hospitalization for worsening HF (HR 2.25, 95% CI 1.14-4.42, p=0.019). Impaired glucose tolerance complicated by albuminuria was associated with a increased risk of the composite primary outcome compared to normal glucose regulation without albuminuria.
Synapse has enriched 10 related papers. Consider them for comparative context: